AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Ionis Pharmaceuticals, Inc.
Video analysis: IONS
All videosNo video analysis for this stock yet. Request one from our team.
News: IONS
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Cathie Wood has bought and sold the stock a lot, so don't follow her blindly. The company posted a loss in its last quarter, but revenue is growing robustly.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down After Analyst Downgrade
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) shares gapped down prior to trading on Tuesday after Morgan Stanley lowered their price target on the stock from $110.00 to $104.00. The stock had previously closed at $58.09, but opened at $52.15. Morgan Stanley currently has an overweight rating on the stock. Ionis Pharmaceuticals shares last
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday.
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
